Psoriasis News and Research

Latest Psoriasis News and Research

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy.

27 Apr 2016

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

About half of Medicare patients who start taking biologic therapies for moderate to severe plaque psoriasis stop within a year, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

26 Apr 2016

MALT1 inhibitors may be useful for treating psoriasis patients with CARD14 mutations

Psoriasis is a long-lasting autoimmune disease that is characterized by patches of abnormal and inflamed skin. It is generally thought to have a genetic origin, which can be further triggered by environmental factors. People with specific mutations in the CARD14 gene have a high probability of developing psoriasis.

25 Apr 2016

Taking antibiotics in early childhood can disrupt immune system function lifelong

Scientists want to know whether taking antibiotics early in life can disrupt your immune system function lifelong.

15 Apr 2016

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.

6 Apr 2016

Novel way of hitting prostate cancer

Researchers at UC Davis, in collaboration with the other institutions, have found that suppressing the nuclear receptor protein ROR-γ with small-molecule compounds can reduce androgen receptor (AR) levels in castration-resistant prostate cancer and stop tumor growth.

29 Mar 2016

Alba’s Post takes new measures to help people with psoriasis

A new online platform, Alba’s Post, is taking new measures in helping people with psoriasis taking control of their disease, by providing information on the effects of nutrition.

23 Mar 2016

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

LEO Pharma today announced that it received scientific approval of Enstilar (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) for the treatment of psoriasis vulgaris in patients 18 years of age or older.

21 Mar 2016

Psoriasis patients experience widespread bone loss

Researchers from the Genes, Development and Disease Group, headed by Erwin Wagner at the Spanish National Cancer Research Centre have discovered that psoriasis patients experience a widespread bone loss as a result of the disease.

17 Mar 2016

Global research links genes to five common, hard-to-treat inflammatory diseases

A global study involving 50 different research centres has found hundreds of genes which cause five common, hard-to-treat and debilitating inflammatory diseases, paving the way to new treatments for these conditions

16 Mar 2016

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Eli Lilly and Company announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab in a Phase 3 clinical trial. Detailed results of the UNCOVER-2 study were presented during the American Academy of Dermatology Annual Meeting taking place March 4-8 in Washington, D.C.

8 Mar 2016

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Eli Lilly and Company announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for ixekizumab for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union who are candidates for systemic therapy.

26 Feb 2016

Remicade co-developer funds new microscopy facility on Scripps Florida campus

The co-developer of Remicade, one of the three top-selling drugs in the world, has donated more than $500,000 to fund what will be known as the Iris and Junming Le Foundation Super-Resolution Microscopy Facility on the Florida campus of The Scripps Research Institute.

30 Jan 2016

Certain viral infections during pregnancy could cause behavioral changes in offspring

A study published in the journal Science found that activation in pregnant mice of a particular immune response, similar to what may occur with certain viral infections during pregnancy, alters the brain structure of the mouse offspring and causes behavioral changes, reminiscent of those observed in humans with autism spectrum disorder (ASD).

30 Jan 2016

Scientists solve atomic structure of ubiquitin ligase complex that plays key role in protein degradation

Scientists at Sanford Burnham Prebys Medical Discovery Institute have solved the atomic structure of a unique ubiquitin ligase complex. Ubiquitin is best known for its role in protein degradation, but more recently seen as important for cell signaling, DNA repair, anti-inflammatory, and immune responses.

21 Jan 2016

Age plays key role when it comes to patients' access to most efficient psoriasis treatment

A new study from Umeå University in Sweden shows that age plays a huge role when it comes to patients' access to psoriasis treatment. Researchers who have examined if patients of varying ages have the same access to the most efficient psoriasis treatment, found that an age increase of 30 years resulted in an average 65 per cent reduction in likelihood of obtaining treatment with biologics.

20 Jan 2016

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel.

19 Jan 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Diabetes is the leading cause of kidney failure, and scientists have found that infusing just a small dose of a cytokine, thought to help cause that failure, can instead prevent or reverse it.

29 Dec 2015

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune Pharmaceuticals Inc. a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies.

29 Dec 2015

Psoriasis News and Research

Latest Psoriasis News and Research

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

MALT1 inhibitors may be useful for treating psoriasis patients with CARD14 mutations

Taking antibiotics in early childhood can disrupt immune system function lifelong

Inflectra (infliximab-dyyb) approved for multiple indications

Novel way of hitting prostate cancer

Alba’s Post takes new measures to help people with psoriasis

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

Psoriasis patients experience widespread bone loss

Global research links genes to five common, hard-to-treat inflammatory diseases

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Remicade co-developer funds new microscopy facility on Scripps Florida campus

Certain viral infections during pregnancy could cause behavioral changes in offspring

Scientists solve atomic structure of ubiquitin ligase complex that plays key role in protein degradation

Age plays key role when it comes to patients' access to most efficient psoriasis treatment

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in